Roivant’s Anti-inflammatory Drug Succeeds in Mid-stage Study

Source link :

(Reuters) – Roivant Sciences said on Tuesday its experimental drug to treat non-infectious uveitis helped reduce symptoms of the inflammatory eye disease in a mid-stage study, sending the biotech firm’s shares up 8% in premarket trading. In the study testing 26 patients, 29% of those who received a higher-strength 45 milligram (mg) dose and 44% […]

Author : News Health

Publish date : 2024-04-02 11:28:22

Copyright for syndicated content belongs to the linked Source.